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Carcinosarcoma recurrenceA 71-year-old woman with suspected endometrial cancer underwent robotic-assisted hysterectomy, bilateral
salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, and infracolic omentectomy revealing a
stage II uterine carcinosarcoma with components of serous adenocarcinoma and undifferentiated spindle cell
sarcoma. There was no evidence of distant metastasis at the time of surgery. However pelvicwashings were pos-
itive formalignant cells. She received adjuvant chemotherapy and vaginal cuff brachytherapy. Fortymonths later
she developed a subcutaneousmass at the location of previous port site whichwas conﬁrmed to be recurrence of
the uterine primary. She subsequently developed additional distantmetastases to the abdominalwall, lungs, and
bone. Port site metastasis (PSM) was the earliest indicator of disseminatedmetastatic disease in this patient. We
review challenges in themanagement of patients with PSM and propose that PSM be considered as a sign of sys-
temic disease even when presenting as an apparently isolated recurrence.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Minimally invasive gynecologic surgery (MIGS) for gynecologic
malignancies was initially challenged regarding safety and efﬁcacy. Dis-
cussions of port-site metastasis (PSM) questioned whether surgeon
technical skill, port-site tumor extraction, local surgical seeding of
port-sites, or pneumoperitoneum contributed to PSMs (Curet, 2004).
The LAP2 trial reported a 0.24% (4/1696) PSM incidence (Walker et al.,
2009, 2012). While uncommon, PSM remains troubling as some ex-
perts consider PSM indicative of advanced disease and poor prognosis
(Zivanovic et al., 2008; Lönnerfors et al., 2013). Many PSMs are present
in the setting of disseminated disease (Zivanovic et al., 2008; Lönnerfors
et al., 2013). National Comprehensive Cancer Network guidelines rec-
ommend surgical excision of resectable, isolatedmetastases and consid-
eration of adjuvant chemotherapy or radiation therapy (National
Comprehensive Cancer Network, 2014). Therefore, administration of
radiation or chemotherapy after surgical treatment of an isolated PSM
is currently individualized based on expert opinion. Here we present
an unusual case of a clinically isolated PSM diagnosed after a long
40 month disease free interval following MIGS staging of an early
stage uterine carcinosarcoma. Tenmonths aftermanagement of the ini-
tial isolated PSM, the patient developed obvious disseminated disease.. This is an open access article underApparently isolated PSM in this patient portended later development
of disseminated disease. Increased reporting of outcomes associated
with clinically isolated PSMmay inﬂuence post-resection management
by increasing utilization of systemic chemotherapy to treat suspected
underlying disseminated disease.
2. Case
A 71 year old woman with body mass index of 21 kg/m2 was
presented with post-menopausal uterine bleeding and underwent
endometrial biopsy, which revealed a high-grade endometrial serous
adenocarcinoma. Computed tomography of the abdomen and pelvis
demonstrated a 3.5 cm uterine mass, and was without evidence of
lymphadenopathy, ascites, or metastasis.
Robotic-assisted total laparoscopic hysterectomy, bilateral salpingo-
oophorectomy, pelvic and para-aortic lymph node dissection, and
infracolic omentectomy was performed without complication. Five ab-
dominal incisions were made for the robotic camera and instruments,
as well as an accessory port. No adnexal masses were appreciated. The
uterus was approximately 8-weeks in size. Electrocautery bilateral
tubal ligationwasﬁrst performed to prevent retrograde cancer cell spill-
age into the peritoneum. Pelvic and para-aortic lymphadenectomies
were then performed. Next, bilateral salpingo-oophorectomy and
hysterectomy were performed. The omentum appeared normal, and
an infracolic omentectomy was performed. All surgical specimens
were removed vaginally without difﬁculty. Port sites were closedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Incisions healed without complication. Pathologic diagnosis was stage
II uterine carcinosarcoma with components of serous adenocarcinoma,
endometrioid adenocarcinoma, undifferentiated carcinoma, and undif-
ferentiated spindle cell sarcoma. The tumor was 2.5 cm in maximum
dimension in the uterine fundus with maximum depth of invasion of
15% of total myometrial thickness and had superﬁcial cervical stromal
invasion. Cytology of pelvic washings was positive for malignant cells.
She received adjuvant high-dose-rate vaginal cuff brachytherapy
(2100 cGy total dose in 3 weekly fractions) between six cycles of pacli-
taxel (135 mg/m2) and ifosfamide (1.6 g/m2) every three weeks, with
three cycles of chemotherapy administered before brachytherapy and
an additional three cycles after brachytherapy.
She remained without evidence of disease for 40 months, when she
presented with a subcutaneous mass on the right lower quadrant at the
location of a previous port-site. Computed tomography of the abdomen
and pelvis demonstrated a 3.5 cm heterogeneousmass in the deep sub-
cutaneous tissues of the right lower quadrant andwaswithout evidence
of other disease (Fig. 1). She underwent surgical resection of the mass,Fig. 1. CT abdomen/pelvis showing port-site recurrence.which extended to the fascia but not the peritoneum,whichwas not en-
tered. Margins were clear. Pathology conﬁrmed metastasis (high grade
adenocarcinoma) consistent with her previous uterine primary (Fig. 2).
She received external beam radiotherapy of 5990 cGy total dose to
the right lower quadrant recurrence site. She declined systemic chemo-
therapy. Five months later, she had a new palpable lump at the right
ﬂank, 3 cm superior to the previous mass. This recurrence developed
in the previously radiated ﬁeld. Positron emission tomography (PET/
CT)was performed and revealed a solitary focus of activity in the super-
ﬁcial right abdominal wall distinct from the previous recurrence site
(Fig. 3). The mass was resected with clean margins and pathology
again conﬁrmed metastasis consistent with the primary diagnosis.
In the presence of severe back pain, she underwent another PET/CT
two months after resection, which revealed new pulmonary nodules
concerning for metastasis and L4 vertebral metastasis. She began
palliative oral etoposide (50 mg alternating with 100 mg for days 1–
21, then 7 days off, every 28 days) chemotherapy. She is currently
alive 53 months from initial diagnosis.
3. Discussion
Many hypotheses have been proposed to explain the development
of PSM including direct wound seeding by specimen removal or con-
taminated instruments, aerosolization of exfoliated cancer cells, the
“chimney effect” caused by insufﬂation, and pneumoperitoneum, car-
bondioxide, or tissue trauma altering the normal immunologic defenses
at port sites (Curet, 2004). There is little evidence to support any prac-
tice to reduce PSM risk (Curet, 2004). The LAP2 trial reported a low
PSM incidence of 0.24%, which is acceptable compared to laparotomy
(Walker et al., 2012; Gücer et al., 2005). Furthermore, the LAP2 trialFig. 2. Histology of PSM (100×) showing adenocarcinoma of primary tumor pathology.
Fig. 3. PET/CT showing new recurrence at right ﬂank abdominal wall, cephalic to location
of previous PSM.
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type (Walker et al., 2012).
Palomba et al. reviewed published data of PSM after staging for en-
dometrial cancer (Palomba et al., 2012). PSM was isolated in 4 cases
and developed with concurrent carcinomatosis in 8 cases. Isolated
PSMwere all endometrioid histology, high grade, and stage I or II at ini-
tial diagnosis. One patient declined excision and underwent palliative
radiation plus hormone therapy before succumbing to disease 5months
later. One patient had excision followed by radiation and was disease
free for 30 months before recurring and dying of disease 42 months
after ﬁrst recurrence. The other two patients had excision, radiation
therapy and chemotherapy. Follow up data was unavailable for one pa-
tient. The secondpatientwas disease free at 10months after recurrence.
Palomba et al. also concluded that apparently isolated PSM may repre-
sent occult, disseminated metastatic disease (Palomba et al., 2012).
Carlson et al. reported an interesting PSM at a right upper quadrant
(RUQ) port-site used for laparoscopic cholecystectomy that was
performed 6 months prior to the patient's staging and diagnosis of
stage IIIC serous ovarian cancer (Carlson et al., 2002). Twenty-seven
months after laparoscopic surgical staging and cytoreduction of the
ovarian malignancy, she developed a PSM at a RUQ port-site from herprior laparoscopic cholecystectomy. The PSM was resected, and she
was given platinum chemotherapy. Six months later she developed a
pelvic recurrence andwas treatedwith additional platinum chemother-
apy. She subsequently remained disease free for three years prior to the
report of her case. The apparently isolated RUQ PSM also preceded the
development of additional metastatic disease despite treatment of the
PSM with resection and systemic chemotherapy.
Uterine carcinosarcoma, although initially considered to be a sarco-
ma, is now recognized as an advanced carcinoma that undergoes
an epithelial-to-mesenchymal transformation (Cantrell et al., 2015). It
is one of the most aggressive types of uterine pathologies, associated
with high recurrence rates and a 5-year survival of 33–39% (Cantrell
et al., 2015). In our case, the patient developed an isolated uterine carci-
nosarcoma PSM after a 40 month disease free interval but before any
indication of systemic disease. Later, she developed an additional ab-
dominal wall metastasis, as well as suspected pulmonary and boneme-
tastases. We believe that her PSM was an early indication of occult
disseminated disease. We propose that when patients develop an ap-
parently isolated PSM, although additional metastases may not yet be
evident by imaging, the presence of PSM indicates high risk for progres-
sion of disease and warrants systemic treatment in additional to local
excision and/or radiation.Wepropose that patientswith apparently iso-
lated PSMwithout evidence of othermetastatic disease require system-
ic chemotherapy in addition to excision and/or radiation therapy to the
site of recurrence. PSM of carcinosarcoma indicates a poor prognostic
condition for the patient and palliative discussions should be initiated.
Best management of isolated PSM is broadly relevant to Gynecologic
Oncology practice. All patients undergoing laparoscopic surgery for can-
cer are at risk for PSM. Case reports, case series and literature reviews
informing expert opinionwill likely remain thehighest level of evidence
for the clinical dilemma of isolated PSM.
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